

Duchenne Muscular Dystrophy (DMD) Market Size in the 7MM to Reach USD 3,906.1 Million by 2035

The report also provides a detailed analysis of the current Duchenne muscular dystrophy marketed drugs and late-stage pipeline drugs.

BROOKLYN, NY, UNITED STATES, June 30, 2025 /EINPresswire.com/ -- How big is the market for Duchenne muscular dystrophy?

The <u>Duchenne muscular dystrophy</u> (<u>DMD</u>) market size reached a value of USD 2,259.0 million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 3,906.1 Million by

The market is exhibiting a

CONTINUOUS growth rate

Market Opportunity (USD)

Duvyat (givinostat) - Italfarmaco

Elevidye (delandistrogene moxeparvovec-roki)

- Savepta Threnpeutics

Emifaza (deflazacort) - Marathon
Pharmaceuticals/PTC Therapeutics

- Eteplizen (Exondys 51) - Sarepta Therapeutics

Eteplizen (Exondys 51) - Sarepta Therapeutics

- PTCI24 (Ataluren) - PTC Therapeutics

- PTCI24 (Ataluren)

Duchenne Muscular Dystrophy Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

2035, exhibiting a growth rate (CAGR) of 5.11% during 2025-2035.

DMD or Duchenne muscular dystrophy is a rare genetic disorder that causes progressive muscle wasting. 2025 DMD market includes gene and molecular therapies, corticosteroids, exonskipping drugs, cell-based therapies, and supportive care. Building awareness and growing appreciation for treating this disorder are driving innovation in the market.

Market Drivers and Barriers to Growth

High DMD incidence and improved genetic screening techniques are increasing the pool of diagnosed patients. Regulatory support in terms of orphan drug designations, fast-track approvals, and conditional approvals is speeding the therapy launches. Also, increased private and public investment in R&D activities, along with pipeline momentum, are supporting the rapid growth.

2025 Market Trends

Gene therapy holds the power to transform DMD treatment. Authorized late in 2024 for non-

ambulatory cases by Sarepta, Elevidys, the first gene therapy for ambulatory DMD patients, currently finds itself under FDA scrutiny following liver-related deaths. While the former are in development, cell therapy products such as Capricor's deramiocel, PTC Therapeutics' exonskipping therapies, and novel corticosteroids like vamorolone (Agamree) and the HDAC inhibitor givinostat (Duvyzat) are pushing through approvals and early access programs.

By 2025, the DMD market is becoming a dynamic sector characterized by state \Box of \Box the \Box art genetic and molecular therapy alternatives. Though gene therapy holds the promise to revolutionize, monitoring for safety remains essential. Novel therapies like exon \Box skipping drugs, corticosteroids with enhanced safety profiles, and cell \Box based therapies support a more diversified treatment environment. Regulatory support and increasing patient access point toward an effective transition toward improved outcomes and long \Box term market expansion in the next decade.

Request for a sample of this report: https://www.imarcgroup.com/duchenne-muscular-dystrophy-market/requestsample

The report also provides a detailed analysis of the current Duchenne muscular dystrophy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Competitive Landscape with key players:

The competitive landscape of the Duchenne muscular dystrophy market has been studied in the report with the detailed profiles of the key players operating in the market.

Italfarmaco Sarepta Therapeutics Marathon Pharmaceuticals/PTC Therapeutics REGENXBIO Edgewise Therapeutics

7 Major Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Elena Anderson IMARC Services Private Limited +1 631-791-1145 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/827005764

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.